Clinical Research Directory
Browse clinical research sites, groups, and studies.
Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery
Sponsor: Saint Petersburg State University, Russia
Summary
PRIORITY is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to ICU) use of fibrinolysis inhibitors leads to a decrease in post-operative blood transfusion compared to a policy that only involves intraoperative use.
Official title: The Practice of Routine Extended Perioperative Administration of Fibrinolysis Inhibitors to Reduce the Risk of Bleeding in Cardiac Surgery. Multicenter Prospective Randomized Cluster Crossover Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1373
Start Date
2024-08-01
Completion Date
2026-06-01
Last Updated
2025-01-27
Healthy Volunteers
No
Interventions
No routine fibrinolysis inhibitors after surgery
Tranexamic acid or epsilon-aminocaproic acid should be administered intravenously during surgery. The dosage and method of administration should be followed according to the routine practice of the participating site.
Routine fibrinolysis inhibitors after surgery
During surgery, it is recommended to administer 70% of the routine dose of Tranexamic acid or epsilon-aminocaproic acid intravenously. Following the surgery, the remaining 30% of this dose should be administered as a continuous intravenous infusion over the course of the first 4 hours.
Locations (2)
Cardiac surgery department, Saint-Petersburg state university hospital
Saint Petersburg, Russia
St. Petersburg State University Hospital
Saint Petersburg, Russia